Thiamine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
(Text replacement - "qd" to "QD") |
||
| Line 8: | Line 8: | ||
*Beriberi | *Beriberi | ||
**10-20mg IM tid x 2wk | **10-20mg IM tid x 2wk | ||
***Then 5-30mg PO | ***Then 5-30mg PO QD x1mo | ||
*Wet beriberi with CHF | *Wet beriberi with CHF | ||
| Line 15: | Line 15: | ||
*Wernicke encephalopathy | *Wernicke encephalopathy | ||
**100mg IV x1 | **100mg IV x1 | ||
***Then 50-100mg IM/IV | ***Then 50-100mg IM/IV QD | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 06:19, 7 July 2017
Administration
- Dosage Forms: 50,100,250,500mg
- Routes of Administration: IM, IV
- Im or IV routres require: Intradermal skin test before use if hypersensitivity risk
- Common Trade Names: Vitamin B1
Adult Dosing
- Beriberi
- 10-20mg IM tid x 2wk
- Then 5-30mg PO QD x1mo
- 10-20mg IM tid x 2wk
- Wet beriberi with CHF
- 10-30mg IV tid
- Wernicke encephalopathy
- 100mg IV x1
- Then 50-100mg IM/IV QD
- 100mg IV x1
Pediatric Dosing
Special Populations
- Pregnancy Rating: A (according to dietary reference intake)
- Lactation risk: Safe
Renal Dosing
Not defined
Hepatic Dosing
Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- angioedema
- cyanosis
Common
- injection site pain
- pruritus
- warmth sensation
- urticaria
Pharmacology
- Half-life: Unknown
- Metabolism: Liver, CYP450, Unknown
- Excretion: Urine
Mechanism of Action
Physiologic cofactor